Publications by authors named "Pascal Minini"

Claim this Profile
V
Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials.
Cynthia J Tifft, Isabela Batsu, Roberto Giugliani, Harmonie Goyeau, Andreas Hahn, Pascal Minini

Genet Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses.
Julie Kissell, Camille Rochmann, Pascal Minini, Florian Eichler, Christopher D Stephen

Mol Genet Metab· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Nir Giladi, Roy N Alcalay, Gary Cutter, Thomas Gasser, Tanya Gurevich, Pascal Minini

Lancet Neurol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
Ronald T Gansevoort, Ali Hariri, Pascal Minini, Curie Ahn, Arlene B Chapman

Am J Kidney Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.
Raphael Schiffmann, Timothy M Cox, Jean-François Dedieu, Sebastiaan J M Gaemers, Julia B Hennermann, Pascal Minini

Brain· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD.
Ronald D Perrone, Ali Hariri, Pascal Minini, Curie Ahn, Arlene B Chapman

Kidney Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.
M Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, Thomas Gasser, Stuart H Isaacson, Pascal Minini

J Parkinsons Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Kausik K Ray, Antonio J Vallejo-Vaz, Henry N Ginsberg, Michael H Davidson, Michael J Louie, Pascal Minini

Atherosclerosis· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
John J P Kastelein, G Kees Hovingh, Gisle Langslet, Marie T Baccara-Dinet, Daniel A Gipe, Pascal Minini

J Clin Lipidol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia.
John J P Kastelein, Dean J Kereiakes, Christopher P Cannon, Harold E Bays, Pascal Minini

Coron Artery Dis· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Burden of Hepatitis in South Korea.
Hugh Watson, Pascal Minini, Jeffrey Encinas

Jpn J Infect Dis· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).
Daniel Gaudet, Gerald F Watts, Jennifer G Robinson, Pascal Minini, William J Sasiela

Am J Cardiol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
Kausik K Ray, Henry N Ginsberg, Michael H Davidson, Robert Pordy, Laurence Bessac, Pascal Minini

Circulation· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials.
Michel Farnier, Daniel Gaudet, Velichka Valcheva, Pascal Minini, Kathryn Miller

Int J Cardiol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
Philippe Gabriel Steg, Shamir R Mehta, Charles V Pollack, Christoph Bode, Marc Cohen, Pascal Minini

JAMA· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bleeding risk in patients with atrial fibrillation: the AMADEUS study.
Deirdre A Lane, Pieter W Kamphuisen, Pascal Minini, Harry R Büller, Gregory Y H Lip

Chest· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.
Florence Wong, Pere Gines, Hugh Watson, Yves Horsmans, Paolo Angeli, Pascal Minini

J Hepatol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity analysis of longitudinal binary data with non-monotone missing values.
Pascal Minini, Michel Chavance

Biostatistics· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity analysis of longitudinal normal data with drop-outs.
Pascal Minini, Michel Chavance

Stat Med· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Multiplicity of inferences in clinical trials: adjustment methods, clinical interpretation issues].
Chrystel Jouan-Flahault, Florence Casset-Semanaz, Pascal Minini

Med Sci (Paris)· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthma.
Christian Roux, Sami Kolta, Jean-Luc Desfougères, Pascal Minini, Etienne Bidat

Pediatrics· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis